BPSI, Scentryphar Join Clinical Forces in Brazil

BioPharma Services Inc. (BPSI) has entered into a partnership and joint venture agreement with Scentryphar, a CRO located in Sao Paulo, Brazil. The partnership aims to support local and global sponsors’ generic and innovative drug development in the Brazilian market by offering joint expertise in clinical conduct, bioanalysis, data management, statistics as well as scientific and medical writing.

BPSI is a physician-owned CRO that specializes in Phase I/IIa trials, including FIM trials, BE studies and bioanalysis, for international pharmaceutical and biotech companies from the U.S., Canada, Australia and Europe. Scentryphar specializes in clinical pharmacology and has worked with Phases I, III, IV and bioequivalence studies for Brazilian and international companies.

“We are extremely pleased to partner with Scentryphar to offer generic and Phases I-IV project management for Brazilian submission. This strategic alliance will allow our sponsors to bring products in Brazil in a timely fashion while maintaining high quality standards,” said Mr. Renzo DiCarlo, chief executive officer at BPSI.

“We are honored to partner with BPSI which has a great international reputation in the industry and with many regulatory agencies including US FDA, Health Canada and EMA. Working with BPSI will position both companies as leading CRO’s in Brazil,” said Dr. Eduardo Abib Jr., president and chief executive officer at Scentryphar.